Uncoupling of Human Cardiac β-Adrenoceptors During Cardiopulmonary Bypass With Cardioplegic Cardiac Arrest

Dietmar Schranz, MD; Annette Droege; Andrea Broede; Götz Brodermann; Ellen Schäfer; Hellmut Oelert, MD; and Otto-Erich Brodde, PhD

**Brief Rapid Communication**

Cardiopulmonary bypass (CPB) is a process routinely used during cardiac surgery. During CPB, after aortic cross-clamping, the myocardium is cooled, arrested, by means of cardioplegic solution, and deprived of its native blood. It has repeatedly been reported that endogenous catecholamines are vigorously increased during CPB.1-11 In addition, it has been demonstrated that norepinephrine is released from anoxic, isolated hearts5 and that cooling maintains elevated catecholamines in ischemic myocardium.6 Accordingly, on termination of CPB, myocardial tissue may have been exposed locally to increased catecholamine levels, and rewarmed un-cross-clamped heart is perfused by blood containing markedly elevated levels of catecholamines. Since continuous exposure of β-adrenoceptors to β-adrenoceptor agonists (including elevation of endogenous catecholamines) causes desensitization and, finally, downregulation of β-adrenoceptors,6-8 it may well be that the increase in catecholamines during CPB with cardioplegic cardiac arrest causes desensitization of cardiac β-adrenoceptors. Two recent studies in patients undergoing cardiac surgery have shown that in circulating lymphocytes, β1-adrenoceptors were desensitized after CPB.10,11 However, it is not known whether human cardiac β-adrenoceptors (which are mainly of the β1-subtype; for a recent review, see Reference 12) are affected by CPB, and alterations of β2-adrenoceptors in circulating lymphocytes are certainly not a good model to predict β-adrenoceptor changes in the human heart.13 Therefore, in the present study, we determined in 12 children undergoing open-heart surgery the effects of CPB with cardioplegic cardiac arrest on right atrial β-adrenoceptor density, β-adrenoceptor subtype distribution, and functional responsiveness (assessed by right atrial adenylate cyclase activation by the β-adrenoceptor agonist isoprenaline and various non-receptor-mediated activators).

**Methods**

Right atrial appendages were obtained from 12 children (six females and six males; mean age, 4.6±1.3 years; age range, 0.75–17 years) with cyanotic congenital heart disease who underwent open-heart surgery because of ventricular septal defect (n=5), atroventricular septal defect (n=2), atrial septal defect (n=1), tetralogy of Fallot (n=3), or aortic stenosis (n=1). Their parents had given informed written consent. None of the children suffered from acute heart failure or had been treated with sympathomimetic (i.e., catecholamines) or parasympathomimetic drugs for at least 3

**Background.** It is well known that during cardiopulmonary bypass (CPB) with cardioplegic cardiac arrest, catecholamines are vigorously increased. We therefore investigated whether this might cause desensitization of human cardiac β-adrenoceptors.

**Methods and Results.** We assessed in 12 children with cyanotic congenital heart disease who underwent open-heart surgery right atrial β-adrenoceptor number and subtype distribution [by (−)-(125I)iodocyanopindolol binding] and adenylate cyclase activation [by the β-adrenoceptor agonist isoprenaline (100 µM) and by the non–receptor-mediated activators 10 µM GTP, 10 mM NaF, 100 µM forskolin, and 10 mM Mn2+]11 before and after CPB with a cardiac arrest by means of St. Thomas' cardioplegic solution. CPB affected neither β-adrenoceptor number or subtype distribution nor GTP, NaF, forskolin, or Mn2+–induced activation of adenylate cyclase. In contrast, activation of adenylate cyclase by 100 µM isoprenaline was significantly (p=0.0249) lower after CPB than before CPB.

**Conclusions.** CPB with cardioplegic cardiac arrest decreases β-adrenoceptor–mediated adenylate cyclase activation in a manner compatible with an uncoupling of β-adrenoceptors from the G-protein–adenylate cyclase complex. Such a β-adrenoceptor desensitization may be the reason why after CPB many patients need inotropic support but do not respond sufficiently to catecholamines. (Circulation 1993;87:422–426)

**KEY WORDS** • β-adrenoceptors, human cardiac • desensitization • cardiopulmonary bypass

*From the Department of Internal Medicine (A.D., A.B., E.S., O.-E.B.), University of Essen; the Department of Pediatrics (D.S., G.B.), University of Mainz; and the Department of Cardiothoracic Surgery (H.O.), University of Mainz, Germany.

Supported by the Deutsche Forschungsgemeinschaft (DFG Br 526/3-1).

Address for correspondence: Otto-Erich Brodde, PhD, Biochem. Forschungslabor, Med. Klinik und Poliklinik, Abt. G, Nieren- und Hochdruckkrankheiten, Universitätssklinikum, Hufelandstraße 55, D-4300 Essen 1, FRG.

Received May 7, 1992; revision accepted October 13, 1992.
weeks before surgery. Some children were treated with spironolactone (n=3), furosemide (n=2), and digitalis glycosides (n=3), either alone or in combination.

Anesthesiological premedication usually consisted of 50-100 µg/kg flunisolide p.o. administered in the evening before surgery or in the morning of surgery. The operation was carried out under neuraxial anesthesia with boluses of flunisolide (50 µg/kg) and fentanyl (10–25 µg/kg). Pancuronium (100 µg/kg) was used as a muscle relaxant. Controlled ventilation was performed with an inspired oxygen fraction of 50–100%.

Several children were also pretreated with either glycosides (n=3) or 50–100 mM NaCl (n=3) before the end of the operation. The solutions were infused intravenously through a central venous catheter. The infusion was stopped immediately before the end of surgery.

Radioligand-Binding Studies

Tissues (mean wet weight, 25.5±3.6 mg; range, 4.3–65.3 mg) were minced with scissors and homogenized in 10 vol of ice-cold 1 mM KHCO₃ with an Ultra Turrax (Janke & Kunkel, Staufen, Germany) for 10 seconds at full speed and twice for 20 seconds at half-maximal speed at 1-minute intervals. The homogenate was diluted to 20 ml with 1 mM KHCO₃, passed through four layers of cheesecloth, and centrifuged at 50,000g for 30 minutes. For β-adrenoceptor determination, the final pellets were resuspended in 10 mM Tris-HCl buffer (pH 7.4) containing 0.55 mM ascorbic acid at a protein concentration of 0.1–0.2 mg/ml. Protein content was determined by the method of Bradford using bovine immunoglobulin G as a standard.

The density of β-adrenoceptors in atrial membranes was determined by (-)[³²P]Iodocyanopindolol (ICYP) binding at six concentrations of ICYP ranging from 5 to 200 pM as recently described. Nonselective binding of ICYP was defined as binding to membranes, which was not displaced by a high concentration of the nonspecific β-adrenoceptor antagonist (±)-CGP 12177 (1 µM). Specific binding of ICYP was defined as total binding minus nonspecific binding; it usually was 70–80% at 50 pM ICYP.

To determine the relative amount of β₁- and β₂-adrenoceptors, membranes were incubated with ICYP (100 pM) in the presence or absence of eight concentrations (ranging from 10⁻¹⁰ to 10⁻³ M) of the highly selective β₁-adrenoceptor antagonist CGP 20712 A, and specific binding was determined as described above.

CGP 20712 A competition curves were analyzed by the iterative curve-fitting program INPLOR (GraphPad software, San Diego, Calif.). Statistical analysis was performed using the F ratio test to measure the goodness of fit of the competition curves for one or two sites.

Adenylate Cyclase Determination

Adenylate cyclase activity was assessed as described by Salomon et al. with minor modifications as detailed elsewhere. Three different incubation conditions were used. For isoprenaline activation, membranes (30–40 µg protein) were incubated for 10 minutes at 37°C in a final volume of 100 µl containing 40 mM HEPES buffer (pH 7.4), 5 mM MgCl₂, 1 mM EDTA, 10 µM GTP, 500 µM [α³²P]ATP, 100 µM cyclic AMP (cAMP), and an ATP-regenerating system (5 mM phosphocreatine and 50 units/ml creatine phosphokinase; buffer A). For GTP, NaF, and forskolin activation, membranes were incubated in buffer A without GTP; for Mn²⁺ activation, membranes were incubated in buffer A without GTP and Mg²⁺. The reaction was stopped by adding 0.8 ml of 50 mM Tris-HCl buffer (pH 7.4) containing 40 mM ATP and 1.4 mM cAMP. [³H]cAMP (5,000–10,000 cpm) was then added to monitor the recovery of [³H]cAMP.

Statistical Analysis

We included results in data evaluation only from children from whom tissue was sufficient to perform measurements simultaneously in "before" and "after" right atria. The experimental data given in the text and figures are expressed as mean±SEM of 12 (β-adrenoceptor density and subtype distribution) and 10 (adenylate cyclase) experiments. The equilibrium dissociation constants (Kᵦₒ) and the maximal number of binding sites (Bₘₐₓ) for ICYP were calculated from plots according to Scatchard. The significance of differences was estimated by nonpaired Student's t test. A value of p<0.05 was considered significant.

Study Drugs

CGP 20712 A (1-[2-((3-carbamoyl-4-hydroxy)phenoxy)-ethylamino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazol-5-yl)phenoxy]-2-propanol methylsulfonate) and (-)-CGP 12177 hydrochloride (4-(3-tertiarybutylamino-2-hydroxypropoxy)-benzimidazole-2-son) were gifts of CIBA-GEIGY (Basel, Switzerland). (-)-[³²P]Iodocyanopindolol (ICYP; specific activity, 2,200 Ci/mmol), [α³²P]ATP (specific activity, 30 Ci/mmol), and [³H]cAMP (specific activity, 44.5 Ci/mmol) were obtained from New England Nuclear (Drerich, Germany). Isoprenaline bitartrate and forskolin were obtained from Sigma Chemical (Deisenhofen, Germany). All other chemicals were of the highest purity grade commercially available.

Results

β-Adrenoceptor Density

The mean number of “before” right atrial β-adrenoceptors amounted to 79.4±8.8 fmol ICYP specifically bound/mg protein (n=12), and the mean β₁-β₂-adrenoceptor ratio was 67.4±3.5/32.6±3.5% (n=12). CPB with cardiopulmonary arrest did not significantly affect β-adrenoceptor density (after: 73.6±10 fmol/mg protein) or β₁-β₂-adrenoceptor ratio (70.3±3.1/29.9±3.1%) (Fig-
Figure 1. Bar graphs of the effects of cardiopulmonary bypass (CPB) with cardioplegic cardiac arrest on β-adrenoceptor density and β₁/β₂-adrenoceptor ratio in right atria from children undergoing open-heart surgery. For details, see “Methods.” Left ordinate: Right atrial β-adrenoceptor density in fmol/(-)[125I]iodocyanopindolol (ICYP) specifically bound/mg protein. Right ordinate: Right atrial β₁/β₂-adrenoceptor ratio in percent. Values are mean±SEM of 12 experiments.

ure 1). Similarly, Kₐ values for ICYP were not changed (before: 9.1±1.0 pM; after: 9.6±0.7 pM).

Adenylate Cyclase Activity

Basal adenylate cyclase activity determined in membranes from “before” right atria (93.6±19 pmol cAMP formed/mg protein/min, n=10) was nearly identical with that obtained in “after” right atria (93.9±20 pmol cAMP formed/mg protein/min). Figure 2 shows the effects of CPB with cardioplegic cardiac arrest on β-adrenergic (isoprenaline) as well as non-receptor-mediated activation of adenylate cyclase. Activation of adenylate cyclase by non-receptor-mediated activators (10 μM GTP, 10 μM forskolin, 10 mM NaF, and 10 mM MgCl₂) was not significantly affected. In contrast, in all except one child, CPB reduced β-adrenoceptor-mediated activation of adenylate cyclase; the net increase in adenylate cyclase activity evoked by 100 μM isoprenaline was in “after” right atrial membranes (64.4±14 pmol cAMP formed/mg protein/min) significantly lower than in “before” right atrial membranes (128±22 pmol cAMP formed/mg protein/min, n=10, p=0.0249).

Figure 2. Bar graph of effects of cardiopulmonary bypass (CPB) with cardioplegic cardiac arrest on adenylate cyclase activity in right atria from children undergoing open-heart surgery. For details, see “Methods.” Right ordinate: Right atrial adenylate cyclase activity in pmol cyclic AMP (cAMP) formed/mg protein/min. Values are mean±SEM of 10 experiments. B, basal adenylate cyclase activity; ISO, isoprenaline; F, forskolin. *p=0.0249 vs. before CPB.

Figure 3. Plot of inhibition of (-)[125I]iodocyanopindolol (ICYP) binding in pooled membranes from three before (PRE-) and four after (POST-) right atria by isoprenaline. Membranes were incubated in duplicates in 50 mM Tris-HCl and 10 mM MgCl₂ buffer (pH 7.4) with 100 pM ICYP in the absence and presence of 16 different concentrations of isoprenaline, and specific binding was determined as described in “Methods.” Ordinate: ICYP bound in percent. Abscissa: Molar concentrations of isoprenaline. Nonlinear regression analysis of the competition curves with the iterative curve-fitting program INPLOT revealed that the curves were fitted significantly better to interaction with two classes of binding sites than with a single class of binding sites. From this fit, the following Kᵣ values for isoprenaline were calculated: PRE-atria high affinity, 1.1 nM; low affinity, 235 nM; POST-atria high affinity, 1.1 nM; low affinity, 446 nM. The percentage of high-affinity state was 44.8% in PRE-atria and 20.3% in POST-atria. CPB, cardiopulmonary bypass.

Discussion

In the present study, CPB and cardiac arrest by cold (4°C) St. Thomas’ cardioplegic solution did not affect β-adrenoceptor number or β₁/β₂-adrenoceptor ratio in right atria from children undergoing corrective cardiac surgery but did significantly depress isoprenaline-induced activation of adenylate cyclase. On the other hand, activation of adenylate cyclase by 10 μM GTP and 10 mM NaF (which is believed, in this concentration, to activate predominantly G protein (9)), 100 μM forskolin (acting predominantly at the catalytic unit of the enzyme but involving at least partly G (20)), and 10 mM MnCl₂ (acting at the catalytic unit of the enzyme) was not at all affected during CPB. β-Adrenoceptor number also did not change. These results, therefore, suggest that after CPB, the relation between right atrial β-adrenoceptors and G protein has been altered in manner compatible with an uncoupling of the β-adrenoceptor from the G protein—the first step in agonist-induced β-adrenoceptor desensitization (10). In favor of this idea is the result of (unfortunately, only one was performed because of lack of tissue) one experiment performed in pooled membranes from three “before” and four “after” right atria, which revealed that in “after” right atria, the high-affinity state for isoprenaline (as assessed from competition curves with ICYP binding) that is essential for coupling β-adrenoceptors to adenylate cyclase (21) amounted only to 20.3% of the β-adrenoceptors compared with 44.8% in “before” right atria (Figure 3). Because we did not measure G protein amount or function directly, we cannot fully exclude the possibility that changes in G protein may—at least in part—contribute to the reduction in isoprenaline-induced adenylate cyclase activation after CPB.
In the human heart, adenylate cyclase is much more efficiently coupled to β2-adrenoceptors than to β1-adrenoceptors (see Reference 12). Thus, perhaps CPB-induced decrease in isoprenaline-induced activation of adenylate cyclase reflects desensitization of mainly right atrial β1-adrenoceptors. Such a more pronounced β2-adrenoceptor desensitization would be in agreement with recently published data showing that in rats and Guinea pigs during chronic isoprenaline infusion, cardiac β2-adrenoceptors are more rapidly and to a greater extent downregulated than are cardiac β1-adrenoceptors. 22-24 On the other hand, in “after” atrial membranes, the proportion of isoprenaline-induced high-affinity state of the β1-adrenoceptors was markedly reduced (Figure 3). Because isoprenaline is in functional and binding studies approximately sixfold as β1-adrenoceptor selective, 1,25-27 and the human right atrium contains twice as many β1-adrenoceptors than β2-adrenoceptors (Figure 1; see also Reference 12), this favors the idea that β1-adrenoceptors also are desensitized.

This is, to our best knowledge, the first report describing a desensitization of cardiac β-adrenoceptors during CPB with cardioplegic cardiac arrest in humans. Although we could not determine plasma catecholamines in the children, it is quite likely that the well-known increase in catecholamines during CPB with cardioplegic cardiac arrest, as discussed, explains this β-adrenoceptor desensitization, although other factors may be also involved. Thus, during CPB, cardiac tissue undergoes hyperperfusion and hypothermia that might affect β-adrenoceptor function. Furthermore, a possible influence of the anesthetic agents administered cannot be completely ruled out since some anesthetics can modify the properties of membranes. 28 However, it is quite unlikely that this contributes considerably to CPB-induced right atrial β-adrenoceptor desensitization since halothane, for example, has been found to decrease human lymphocyte β1-adrenoceptor density in vitro by only approximately 10% 27 and has no effect in rat brain. 28

In the present study, CPB-induced changes of β-adrenoceptors were studied in right atria. Whether similar changes also occur with human left ventricular β-adrenoceptors is not known. However, the pattern of changes in β-adrenoceptors and β-adrenergic activation of adenylate cyclase found in human right atria in this study is very comparable to that recently described for canine left ventricular β-adrenoceptors. 29 These authors found that in dogs, a 155-minute CPB did not significantly affect cardiac β-adrenoceptors but did significantly depress isoprenaline- and zinterol-activated adenylate cyclase. They observed, in addition, that by 30 minutes after CPB, β-adrenergic adenylate cyclase activation had returned to normal, whereas the β-adrenoceptor number decreased. Whether similar changes after CPB also occur in humans cannot be assessed. However, it is interesting to note that in the present study, one infant with tetralogy of Fallot and two with atrioventricular septal defect were treated with epinephrine in a dosage ranging from 0.1 to a maximum of 2.0 μg/kg/min for an average of 100 minutes of CPB and showed a low cardiac output. In these three patients, epinephrine had to be continuously infused during the first 16, 22, and 23, respectively, postoperative hours. Interestingly, these three children exhibited much more pronounced decreases in isoprenaline-induced adenylate cyclase activation (“before” CPB: 105±22; “after” CPB: 34±5 pmol cAMP formed/mg protein/min, i.e., 67% decrease) than the other seven children (“before” CPB: 138±31; “after” CPB: 77±18 pmol cAMP/min/mg protein, i.e., 45% decrease). These findings therefore might be taken as an indication that during CPB, β-adrenoceptors desensitize not only in right atrium but also in left ventricular myocardium.

The finding of a desensitization of cardiac β-adrenoceptor function during CPB with cardioplegic cardiac arrest may be of clinical importance. The human heart contains only a few spare receptors for β-adrenoceptor agonist (including endogenous catecholamines)–mediated positive inotropic effects, and nearly all receptors must be occupied to reach a maximal response. 15,30,31 Because of this lack of spare receptors, it is rather plausible that a reduced isoprenaline-induced activation of adenylate cyclase, which results in insufficient increases in cAMP, the second messenger for positive inotropic effects in the human heart, 32 is accompanied by a reduced positive inotropic effect. In fact, it is frequently observed that during weaning from CPB and in the early phase after CPB, patients often need inotropic support that cannot be satisfactorily achieved by β-adrenoceptor agonists.

In conclusion, in children undergoing open-heart surgery, CPB with cardioplegic cardiac arrest causes a reduction in β-adrenoceptor-mediated activation of adenylate cyclase in a manner compatible with an uncoupling of β-adrenoceptors from the G-protein–adenylate cyclase complex. As the human heart contains only a few spare receptors for β-adrenoceptor agonists, such a β-adrenoceptor desensitization may be the reason why many patients need inotropic support after CPB but respond only weakly to β1-adrenoceptor agonists.

References

Uncoupling of human cardiac beta-adrenoceptors during cardiopulmonary bypass with cardioplegic cardiac arrest.
D Schranz, A Droege, A Broede, G Brodermann, E Schäfer, H Oelert and O E Brodde

Circulation. 1993;87:422-426
doi: 10.1161/01.CIR.87.2.422
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1993 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at: http://circ.ahajournals.org/content/87/2/422

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at: http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at: http://circ.ahajournals.org/subscriptions/